Skip to content

Advertisement

  • Erratum
  • Open Access

Erratum to: Optimizing adalimumab treatment in psoriasis with concomitant methotrexate (OPTIMAP): study protocol for a pragmatic, single-blinded, investigator-initiated randomized controlled trial

  • 1Email author,
  • 1,
  • 2,
  • 3,
  • 4,
  • 2,
  • 3,
  • 2 and
  • 1
Contributed equally
Trials201718:113

https://doi.org/10.1186/s13063-017-1848-0

  • Received: 17 February 2017
  • Accepted: 17 February 2017
  • Published:

The original article was published in Trials 2017 18:52

Erratum

The author initials were not complete in the original publication [1].

The correct initials should be: “CI Busard, SP Menting, JS van Bezooijen, JM van den Reek, BA Hutten, EP Prens, EM de Jong, MB van Doorn, PI Spuls”.

Notes

Declarations

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Dermatology, Academic Medical Center, Amsterdam, The Netherlands
(2)
Department of Dermatology, Erasmus University Medical Center, Rotterdam, The Netherlands
(3)
Department of Dermatology, Radboud University Medical Center, Nijmegen, The Netherlands
(4)
Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Academic Medical Center, Amsterdam, The Netherlands

Reference

  1. Optimizing adalimumab treatment in psoriasis with concomitant methotrexate (OPTIMAP): study protocol for a pragmatic, single-blinded, investigator-initiated randomized controlled trial. Trials. 2017;18:52 doi: 10.1186/s13063-017-1777-y.

Copyright

© The Author(s). 2017

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate. Please note that comments may be removed without notice if they are flagged by another user or do not comply with our community guidelines.

Advertisement